Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OrthoSensor, Inc.
Zimmer Biomet and Canary Medical’s FDA de novo clearance of the Persona IQ total knee implant intensifies Zimmer Biomet’s focus on data collection and analytics across continuum of care to improve outcomes and surgery methods, an analyst wrote.
OrthoSensor’s sensor technology complements Stryker’s robotic surgery platform, improves its data-analytics capabilities, and contributes to the development of orthopedic implants with integrated sensors.
The positive hospital inpatient reimbursement decision for recently launched Medtronic and CR Bard peripheral artery devices follows prior positive policy rulings in the outpatient setting. Meanwhile, CMS rejected Boston Scientific's new-technology add-on application for the Watchman stroke device, but the agency did establish a pricier payment category for the new procedure.
Boston Scientific’s Watchman stroke device, Medtronic and Bard’s drug-coated balloons, Cardiovascular Systems atherectomy systems and two other devices each come in for criticism in the Medicare agency’s consideration of the next round of inpatient bonus payments for new technologies.
- Digital Health
- Implantable Devices
- Monitoring Equipment & Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.